Adjuvant treatment with pegylated interferon alpha-2a versus low-dose interferon alpha-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial(aEuro)

摘要

Pegylated-interferon (IFN)-alpha did not improve the outcome over low-dose IFN-alpha in the adjuvant treatment of intermediate and high-risk melanoma patients. A higher percentage of patients under pegylated-IFN-alpha discontinued treatment due to toxicity.Adjuvant treatment with interferon (IFN)-alpha-2a improved disease-free survival (DFS) and showed a trend for improving overall survival (OS) in melanoma. This trial was designed to examine whether PEG-IFN is superior to IFN with regard to distant metastasis-free survival (DMFS), DFS and OS.